US FDA approves extended treatment with Roche's Valcyte in kidney transplant patients
This article was originally published in Scrip
Executive Summary
The US FDA has approved an increased duration of therapy with Genentech's (Roche) oral DNA polymerase inhibitor Valcyte (valganciclovir hydrochloride) in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.